The consequences of advanced chronic kidney disease are severe. When these essential organs can no longer do their job of ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

Oral semaglutide reduced risk for major adverse CV events by 14% in high-risk adults with type 2 diabetes regardless of SGLT2 ...

Rybelsus® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and ...

The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...

While it can affect your body differently when you have diabetes, sugar doesn’t have to be completely off the table.

Injectable semaglutide has better bioavailability, researchers say, but the many patients who want an oral drug are an unmet ...

The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...

Novo Nordisk has submitted a supplemental application to the FDA for Rybelsus 14 mg to lower cardiovascular risk in adults ...

The KidneyMobile is back in Peoria to raise awareness about kidney diseases. March is National Kidney Month. Representatives ...

Wegovy was also associated with a lower risk of hospitalization for heart failure, cardiovascular-related death, and ...